Clinical Trial

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 8, 2023 (before its estimated November 2023 completion). Its status may not reflect the trial's current state.
Summary
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-08-17; most recent amendment 2023-06-06.
Status change: Not Yet Recruiting → Recruiting 2022-10-26
Trial Details
NCT Number NCT04519151
Lead Sponsor Sheba Medical Center
Conditions Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Neoplasm of Stomach, Ovarian Diseases, Genital Neoplasms, Female, Ovarian Epithelial Tumor, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial
Enrollment 24 participants
Start Date 2021-04-12
Primary Completion 2023-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2023-06-08